Current Report Filing (8-k)
January 11 2017 - 3:46PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
January 11, 2017 (January 6, 2017)
MYOS RENS TECHNOLOGY INC.
(Exact name of registrant as specified
in its charter)
Nevada
|
|
000-53298
|
|
90-0772394
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
45 Horsehill Road,
Suite 106 Cedar Knolls, New Jersey
|
|
07927
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including
area code
(973) 509-0444
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.03
|
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
|
Effective January 6, 2017, the board of directors (the “
Board
”)
of MYOS RENS Technology Inc. (the “
Company
”), approved the amendment and restatement of the Company's bylaws
(the “
Amended and Restated Bylaws
”). As the Company’s prior bylaws had not been amended since their adoption
in April 2007, the Amended and Restated Bylaws are intended to conform to current public company practice. The Amended and Restated
Bylaws provide, among other things:
|
·
|
that advance notice of stockholder proposals and stockholder nominations
be submitted to the Company in connection with business intended to be brought before meetings of stockholders;
|
|
·
|
that stockholders provide certain information and comply with other
procedures for stockholder proposals and stockholder nominations;
|
|
·
|
that holders of one-third of the shares of the Company will constitute
a quorum at any meetings of stockholders for the transaction of business;
|
|
·
|
that the Company’s stockholders may not: (i) act by written
consent in lieu of a meeting of stockholders or (ii) call a special meeting of stockholders;
|
|
·
|
that the number of directors on the Board be determined from time
to time by the Board, but shall not be less than one director;
|
|
·
|
that stockholders may remove a member of the Board by the affirmative
vote of holders of 66 2/3% of the issued and outstanding shares of the Company at a duly-called meeting of stockholders;
|
|
·
|
that special meetings of stockholders may be called by the chief executive
officer or secretary only upon the written request of a majority of the Board;
|
|
·
|
for the appointment and removal of officers of the Company;
|
|
·
|
that officers and directors of the Company shall not be personally
liable to the Company, subject to limited exceptions;
|
|
·
|
that the Company is required to indemnify, hold harmless and advance
expenses, to certain indemnitees, subject to limited exceptions;
|
|
·
|
that certain stockholders of record are entitled to inspect certain
records of the Company;
|
|
·
|
that state or federal courts in Las Vegas, Clark Country, State of
Nevada will be the sole and exclusive forum for certain litigation by the stockholders of the Company; and
|
|
·
|
that the Board, and holders of 66 2/3% of the issued and outstanding
shares of the Company at a duly-called meeting of stockholders, can amend the Amended and Restated Bylaws.
|
The foregoing description of the Amended and Restated Bylaws
does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amended and Restated
Bylaws, a copy of which is attached to this Current Report on Form 8-K as Exhibit 3.1 and is incorporated herein by reference.
On January 6, 2017, the Company commenced an action in the Supreme
Court of New York, County of New York, against RENS Technology, Inc., RENS Agriculture Science & Technology Co., Ltd (“RENS
Agriculture”), the parent company of RENS Technology, and Ren Ren, a principal in both entities and a director of the Company,
arising from RENS Technology’s breach of a Securities Purchase Agreement under which RENS Technology agreed to invest an
aggregate of $20.25 million in the Company in exchange for an aggregate of 3,537,037 shares of common stock of the Company and
warrants to purchase an aggregate of 884,259 shares of common stock. In addition to seeking compensatory, consequential and
other damages in the action, the Company asked the Court to preliminarily restrain RENS Technology and its agents and representatives,
including, but not limited to, RENS Agriculture and Ren Ren, from selling, transferring, conveying, assigning, hypothecating or
encumbering 1,500,000 shares of common stock of the Company and a warrant permitting the purchase of 375,000 share at a price of
$7.00 per share that RENS Technology had purchased under the Securities Purchase Agreement and, after the parties had an opportunity
to submit opposition and reply papers in connection with the Company’s application, a preliminary injunction prohibiting
RENS Technology from selling, transferring, conveying, assigning, hypothecating or encumbering the 1,500,000 shares and warrant
during the pendency of the action and an order attaching the stock and warrant to satisfy any judgment entered in favor of the
Company.
On January 11, 2017, the Court granted the Company the preliminary
restraints that it requested, which prevents RENS Technology, among others, from selling, transferring, conveying, assigning, hypothecating
or encumbering the 1,500,000 shares of the Company’s common stock or the aforementioned warrant. The Court scheduled
a hearing on February 14, 2016, at which time the Court will determine whether to issue a preliminary injunction containing the
same relief and order the attachment of the stock and warrant to satisfy any judgment entered in favor of the Company.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
3.1
|
|
Amended and Restated Bylaws of MYOS RENS Technology Inc.
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
MYOS RENS TECHNOLOGY INC.
|
|
|
|
Dated: January 11, 2017
|
By:
|
/s/ Joseph Mannello
|
|
Name:
|
Joseph Mannello
|
|
Title:
|
Interim Chief Executive Officer
|
MYOS RENS Technology (NASDAQ:MYOS)
Historical Stock Chart
From Apr 2024 to May 2024
MYOS RENS Technology (NASDAQ:MYOS)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about MYOS RENS Technology Inc (NASDAQ): 0 recent articles
More Myos Rens Technology Inc. News Articles